Targeting KvS-containing channels selectively could have significant therapeutic implications in various pathological conditions. Since KvS subunits show tissue- and cell-specific expression patterns, drugs targeting these subunits could offer greater specificity in modulating neuronal excitability. This specificity could lead to more targeted treatments for conditions such as epilepsy, neuropathic pain, retinal cone dystrophy, and other disorders where KvS subunits have been implicated. By modulating the activity of subsets of Kv2-expressing cell types, drugs targeting KvS subunits could potentially offer a more refined and effective therapeutic approach with fewer side effects compared to non-specific Kv2-targeted drugs.